Neoadjuvant Dose-Modified Docetaxel in Squamous Cell Carcinoma of the Head and Neck: A Phase 3 Study.
Evaluate the efficacy and safety of dose modified docetaxel plus cisplatin and 5-fluorouracil (TPF) in Chinese patients with squamous-cell carcinoma of the head and neck (SCCHN). This Phase III, open-label, multi-centre study included Chinese adults with previously untreated TNM Stage III or IV SCCHN (NCT00995293). Patients were randomized (1:1) to induction chemotherapy with TPF (docetaxel 60 mg/m2 and cisplatin 60 mg/m2 on day 1, and 5-FU 750 mg/m2 /day continuous IV infusion on days 1-5) or PF (cisplatin 75 mg/m2 on day 1 and 5-FU 750 mg/m2 /day on days 1 to day 5) every 3 weeks for 3-4 cycles. The primary endpoint was progression-free survival (PFS). Median PFS in the TPF (n = 108) and PF (n = 111) groups was 400 days and 342 days (HR = 0.75; 95% CI, 0.53─1.06; p = .227) respectively. Overall response rate was higher for TPF versus PF (76.3% vs. 52.9%; p = .001), although this equalized following radiotherapy (75.0% vs. 73.9%). In the TPF and PF groups, ≥1 treatment emergent adverse event was experienced by 104 (94.5%) and 110 (93.2%) patients, respectively. Adding dose-modified docetaxel to PF did not significantly improve PFS but may increase antitumor activity in Chinese patients with locally advanced SCCHN.